Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.
about
Nonhuman primate models for HIV/AIDS vaccine developmentPoxvirus vectors as HIV/AIDS vaccines in humansThe evolution of poxvirus vaccinesPoxvirus tropismImproved NYVAC-based vaccine vectorsControlling the HIV/AIDS epidemic: current status and global challengesHuman immunodeficiency virus vaccine trialsAntibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trialA double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses.A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapySystemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaquesConstruction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein.Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectorsDistinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry.Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.Developments towards effective treatments for Nipah and Hendra virus infection.Intranasal delivery of vaccines against HIV.An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.Replicating and non-replicating viral vectors for vaccine developmentImmunity and immunological memory following smallpox vaccination.Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDSProtection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency.Targeted strategies for henipavirus therapeuticsDendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors.The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys.Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells.Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16-STING-Type I IFN Pathway and AIM2 Sensor.
P2860
Q26861148-C642352C-1B74-4D92-A223-CEBDDB545B19Q26995078-C53534C7-8CCD-4EF4-8562-32F49BFEF037Q26995905-7DB4F60C-C5CD-4188-9D14-D4B45B5DBA85Q28237434-3326078C-4DEC-4D49-BF49-33FE1707D43AQ28742982-77410232-8427-4D7E-8D77-ED8C4483FEDAQ30420558-440F574B-0DC4-41E3-BB90-C1B2332FBCDDQ30424366-70CB57B0-D6D0-41CD-93B7-5D845D7E663CQ30532861-693BA674-664A-4424-9175-B77F28C4E3C6Q31031447-13BCFCD9-6767-461A-B3A4-CBB66773DB59Q33602820-058CA0B7-7878-434A-A36B-AAE073A2525DQ33645564-964DEFFE-C960-4719-8395-5717B03D3C51Q34546037-A79A83BD-FA89-4F20-A376-3C9AFC080743Q34651266-82766B61-ED18-4AD2-A7BB-F3AB25EEABB0Q34880294-3BC828E0-9F14-43EC-9C87-3B61BCBCBDB6Q35046349-5DD8AB93-CB09-40B4-8D09-3AA1E441BB1CQ35595612-6B3493A9-EBAE-4CDA-A09D-022E39BC733BQ35914427-899F6B04-A3EF-4862-AB53-F6A05DEF4896Q35947683-13DD2B35-B743-4E5E-AD1A-7B427E7DC694Q36060423-EBFFEB43-CD92-4F71-94A2-3CB61FCE5028Q36066251-4564B266-15F0-4DE0-BACA-FAAD4881760FQ36141610-B402E10B-2A40-475C-B1EC-12919F2D3037Q36379335-9322B1D4-9E2D-4905-81A0-5E077FA3750AQ36409054-A82EA82D-B890-4241-942A-1DB051A8568BQ36446900-F7A75E6C-9CEA-45F4-9F21-249964061AB4Q36464587-F7A7EC6D-2648-4CFD-93E6-EF3CA72A34CAQ36529039-CEE2DA1A-4D59-446F-8539-98BB54FAB420Q36667821-397B22C2-8EF0-41BF-B814-B23D4E21CCCAQ36667917-D72E68AB-5E06-423A-98B5-9BA719C87263Q36898836-CC4EE0C5-5B41-4056-B39B-E0E6573FA87FQ37175177-C51B45D6-C894-4083-8880-B2A3683F25BFQ37309247-16BB966E-22B6-4CE7-9469-4E0FEAD6772DQ37547241-A6AAA615-9898-4D58-9CB2-CB2ED0FAA5A5Q37785947-853EA2D0-BBC9-4C0C-A91A-C6BFEBC7D382Q37785949-3B7C04EF-F852-444C-84DA-BB258DDC85F2Q38184579-0B4DA3DA-4636-48AE-B2F8-9F2605DA6E40Q38748193-110503E7-7DC1-4AE1-8FE7-ACD1D1256EE2Q39726192-AEB3DC7C-9584-4959-83D4-74740D3E6F66Q40057846-72CC774F-2A6E-4DE2-AD0C-7C0D2A7B9DCDQ40362454-AF26DF46-0E60-469A-A714-0CD9D59067FFQ41930373-A91BD6B0-6ABF-4398-B7FC-894DDAE2265E
P2860
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Poxvirus-based vaccine candida ...... emphasis on canarypox vectors.
@ast
Poxvirus-based vaccine candida ...... emphasis on canarypox vectors.
@en
type
label
Poxvirus-based vaccine candida ...... emphasis on canarypox vectors.
@ast
Poxvirus-based vaccine candida ...... emphasis on canarypox vectors.
@en
prefLabel
Poxvirus-based vaccine candida ...... emphasis on canarypox vectors.
@ast
Poxvirus-based vaccine candida ...... emphasis on canarypox vectors.
@en
P2093
P2860
P356
P1476
Poxvirus-based vaccine candida ...... emphasis on canarypox vectors.
@en
P2093
Genoveffa Franchini
Jim Tartaglia
Lynn Baglyos
Sanjay Gurunathan
P2860
P304
P356
10.1586/14760584.3.4.S75
P433
P577
2004-08-01T00:00:00Z